“As we think about the second half of the year though, we do expect shipments to China to be less than they were in the first half of the year and therefore expect the second half of the year growth to be slower than what we've achieved in the first half.”

In context

“ator in the near term. This is a longer-term play. Peter Dannenbaum: Thanks, Geoff. Next question please, Cedric. Operator: Yes. Our next question comes from Mohit Bansal with Wells Fargo. Your line is open. Mohit Bansal: Okay. Thanks very much for taking my question. My question is regarding the onetime items. So Caroline, you mentioned regarding China for GARDASIL, as well as KEYTRUDA in the U.S. Would you be able to quantify this a little bit? Just trying to understand the magnitude of how much is impacted by those onetime items. Thank you. Caroline Litchfield: Yes, of course, Mohit. Thank you for the question. So first, talking about GARDASIL, there were no onetime items in the quarter for GARDASIL. We had exceptional growth, that growth was driven by every geography around the world. As we think about the second half of the year though, we do expect shipments to China to be less than they were in the first half of the year and therefore expect the second half of the year growth to be slower than what we've achieved in the first half. For KEYTRUDA, we had a very strong quarter, and that strength was across all indications, including the earlier-stage cancer indications that we’re launching. In the United States, we had sales of $3.9 billion, a growth of 21%. Now that growth included approximately $50 million of benefit because wholesaler buy-in in the second quarter of 2023 was slightly higher than the buy-in we saw in the second quarter of 2022. One of the distributors who has brought in has indicated that they expect to buy out in the third quarter. And the quantum of that buyout has been indicated to be $150 million. That said, we continue to expect strong growth from KEYTRUDA given the current indications we have as well as new launches to come. Peter Dannenbaum: Thanks, Mohit. Next question please, Cedric. Operato”